title: Targeted therapy in esophageal cancer.
abstract: An increasing number of patients are diagnosed with esophageal cancer at an advanced stages, and only a small group of them can benefit from the traditional chemotherapy and radiotherapy. So far, multiple monoclonal antibodies and tyrosine kinase inhibitors have been developed, alone or in combination with traditional therapy, to improve the prognosis of patients with advanced esophageal cancer. This review summarizes the recent advances of targeted therapies against EGFR, HER2, VEGFR and c-MET in esophageal cancer. More clinical trials should be performed to evaluate the efficacy and safety of various targeted therapy regimens. Future basic research should focus on investigating the molecular mechanisms of therapeutic targets in esophageal cancer.
authors.affiliation: a Xijing Hospital of Digestive Diseases , Fourth Military Medical University , Xi'an , China.|b Department of General Surgery , NO. 406 Hospital, Da Lian , China.
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.affiliation: a Xijing Hospital of Digestive Diseases , Fourth Military Medical University , Xi'an , China.
authors.forename: Jiaojiao
authors.initials: J
authors.lastname: Ma
authors.affiliation: c Department of Otolaryngology , Xijing Hospital, Fourth Military Medical University , Xi'an , China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Han
authors.affiliation: a Xijing Hospital of Digestive Diseases , Fourth Military Medical University , Xi'an , China.
authors.forename: Jinqiang
authors.initials: J
authors.lastname: Liu
authors.affiliation: a Xijing Hospital of Digestive Diseases , Fourth Military Medical University , Xi'an , China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhou
authors.affiliation: a Xijing Hospital of Digestive Diseases , Fourth Military Medical University , Xi'an , China.
authors.forename: Liu
authors.initials: L
authors.lastname: Hong
authors.affiliation: a Xijing Hospital of Digestive Diseases , Fourth Military Medical University , Xi'an , China.
authors.forename: Daiming
authors.initials: D
authors.lastname: Fan
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D020022:Genetic Predisposition to Disease; D006801:Humans; D025202:Molecular Diagnostic Techniques; D058990:Molecular Targeted Therapy; D010641:Phenotype; D057285:Precision Medicine; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D047428:Protein Kinase Inhibitors; D019859:Proto-Oncogene Proteins c-met; D018719:Erb-b2 Receptor Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; C512478:EGFR protein, human; C508053:ERBB2 protein, human; C491743:MET protein, human
keywords: EGFR; Esophageal cancer; HER2; Targeted therapy; VEGFR; c-MET